Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gideon M Blumenthal

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
JAMA Oncology|June 30, 2017
Treatment Beyond Progression With Immune Checkpoint Inhibitors-Known UnknownsGideon M Blumenthal, Marc R Theoret, Richard Pazdur
Cancer Journal (Sudbury, Mass.)|May 26, 2018
The First Year of the Food and Drug Administration Oncology Center of Excellence: Landmark Approvals in a Dynamic Regulatory EnvironmentKirsten B Goldberg, Gideon M Blumenthal, Richard Pazdur
Nature Reviews. Cancer|March 25, 2011
PTEN loss in the continuum of common cancers, rare syndromes and mouse modelsM Christine Hollander, Gideon M Blumenthal, Phillip A Dennis
Clinical Pharmacology and Therapeutics|February 7, 2019
Model-Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First-Line Anaplastic Lymphoma Kinase + Non-Small Cell Lung CancerPeter N Morcos, Jiang Liu, Gideon M Blumenthal, et al.
JAMA Oncology|July 26, 2019
Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung CancerDickran Kazandjian, Yutao Gong, Patricia Keegan, et al.
Experimental Biology and Medicine (Maywood, N.J.)|November 7, 2017
The FDA Oncology Center of Excellence and precision medicineKirsten B Goldberg, Gideon M Blumenthal, Amy E McKee, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 2, 2008
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerationsJaclyn LoPiccolo, Gideon M Blumenthal, Wendy B Bernstein, et al.
Seminars in Oncology|April 12, 2017
Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trialsDickran Kazandjian, Patricia Keegan, Daniel L Suzman, et al.
The Oncologist|March 31, 2016
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1Joohee Sul, Gideon M Blumenthal, Xiaoping Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2016
FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung CancerDickran Kazandjian, Gideon M Blumenthal, Weishi Yuan, et al.
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
JAMA Oncology|June 30, 2017
Treatment Beyond Progression With Immune Checkpoint Inhibitors-Known UnknownsGideon M Blumenthal, Marc R Theoret, Richard Pazdur
Cancer Journal (Sudbury, Mass.)|May 26, 2018
The First Year of the Food and Drug Administration Oncology Center of Excellence: Landmark Approvals in a Dynamic Regulatory EnvironmentKirsten B Goldberg, Gideon M Blumenthal, Richard Pazdur
Nature Reviews. Cancer|March 25, 2011
PTEN loss in the continuum of common cancers, rare syndromes and mouse modelsM Christine Hollander, Gideon M Blumenthal, Phillip A Dennis
Clinical Pharmacology and Therapeutics|February 7, 2019
Model-Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First-Line Anaplastic Lymphoma Kinase + Non-Small Cell Lung CancerPeter N Morcos, Jiang Liu, Gideon M Blumenthal, et al.
JAMA Oncology|July 26, 2019
Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung CancerDickran Kazandjian, Yutao Gong, Patricia Keegan, et al.
Experimental Biology and Medicine (Maywood, N.J.)|November 7, 2017
The FDA Oncology Center of Excellence and precision medicineKirsten B Goldberg, Gideon M Blumenthal, Amy E McKee, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 2, 2008
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerationsJaclyn LoPiccolo, Gideon M Blumenthal, Wendy B Bernstein, et al.
Seminars in Oncology|April 12, 2017
Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trialsDickran Kazandjian, Patricia Keegan, Daniel L Suzman, et al.
The Oncologist|March 31, 2016
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1Joohee Sul, Gideon M Blumenthal, Xiaoping Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2016
FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung CancerDickran Kazandjian, Gideon M Blumenthal, Weishi Yuan, et al.
Pageof 9